Real-world data (RWD) is reshaping how pharma discovers, develops and delivers treatments - yet most organisations still capture only a fraction of its value. Our new whitepaper reveals why the barrier isn’t data itself, but the operating model behind it. Discover how leading companies are evolving evidence planning, scaling global access and treating data as a strategic asset.
Download the paper to learn how to unlock full RWD value
Key insights
Based on benchmarking across 10 global pharma companies and interviews with 36 senior leaders spanning R&D, medical, commercial and market access.
Despite recognising RWD’s strategic value (importance rated 4.3/5), actual usage across decision areas remains significantly lower (often <3.5).
Three structural barriers hold companies back: inaccessible and geography-limited data, fragmented internal ownership leading to duplicate purchases, and immature global coverage.
Leaders agree the solution lies in rethinking the operating model — centred on data-as-an-asset, democratised access, and scalable global data acquisition.
Organisations with mature RWD operating models achieve faster decisions, reduced development risk, stronger payer positioning and significantly higher ROI on data investments.
